Revolutionizing Allergy Treatment: Revelation Biosciences Inc. Releases Promising Results from REVTX-99B Phase 1b CLEAR Clinical Study
Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Disease SAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB), a clinical-stage life sciences company, revealed groundbreaking topline data for its Phase 1b CLEAR clinical study. The study focused on evaluating the effect…